dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatita, atopică - alte preparate dermatologice - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
adtralza 150 mg
leo pharma a/s - danemarca - tralokinumabum - sol. inj. in seringa preumpluta - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
cibinqo 100 mg
pfizer manufacturing deutschland gmbh - germania - abrocitinibum - compr. film. - 100mg - preparate de uz dermatologic alte preparate de uz dermatologic
cibinqo 200 mg
pfizer manufacturing deutschland gmbh - germania - abrocitinibum - compr. film. - 200mg - preparate de uz dermatologic alte preparate de uz dermatologic
cibinqo 50 mg
pfizer manufacturing deutschland gmbh - germania - abrocitinibum - compr. film. - 50mg - preparate de uz dermatologic alte preparate de uz dermatologic
dupixent 200 mg
sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
dupixent 200 mg
sanofi-aventis deutschland gmbh - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
dupixent 300 mg
sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic
dupixent 300 mg
sanofi winthrop industrie - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic